secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001493152-25-011882
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering
--------------------------------------------------------------------------------

- Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.
- GAAP net loss $7.9M ($0.08 EPS); non-GAAP adjusted loss $9.9M ($0.10 EPS).
- Ended Q2 with $31.1M cash after $16.1M public offering; runway extended into 2026.
- Medicare contractor advisory committee meeting scheduled September 4 for EsoGuard coverage.
- Partnered with Hoag for esophageal precancer testing; joined Russell 2000/3000 indexes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/0001493152-25-011882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer